In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

The firm's chief scientific officer called the achievement "a major milestone for Spirovant and for the cystic fibrosis ...

Watford fan Josh says meeting DanTDM while in Great Ormond Street due to cystic fibrosis was “one of the coolest things I’ve ...

ReCode is set to secure up to $15m in funding from the Cystic Fibrosis Foundation to enhance its gene correction research ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel ...

VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Arcturus Therapeutics expects interim results for LUNAR-CF and LUNAR-OTC in 2025. Learn why ARCT stock presents an ...

Spirovant Sciences has announced the commencement of its SAAVe Phase I/II study, with the first patient receiving a dose of ...

and others are evaluating new non-cystic fibrosis bronchiectasis drugs to improve the treatment landscape. Promising pipeline non-cystic fibrosis bronchiectasis therapies such as Colistimethate sodium ...